For example, nanoparticles functionalized with anti-PD-1 antibodies offer a promising strategy in cancer immunotherapy by blocking the interaction between the programmed cell death protein 1 (PD-1) receptor on T cells and its ligands on tumor cells. This evidence concerns the gene PDCD1 and neoplasm.